Quick guide

Diagnostic approach

  • ABCDE survey
  • Targeted clinical evaluation
  • CBC
  • BMP
  • ABG
  • Lactate
  • Coagulation studies
  • Type and screen
  • Sepsis workup (e.g., urinalysis, blood cultures)
  • CXR
  • POCUS: cardiac, lung, IVC, FAST
  • See “Further diagnostic studies for patients in shock.”

Begin treatment in tandem with clinical evaluation and diagnostics.

Initial management

  • IV access
  • Hemodynamic monitoring
  • Hemodynamic support (e.g., IV fluid resuscitation, vasopressors)
  • Oxygen therapy as indicated
  • Treat immediately life-threatening causes.
  • Classify the type of shock; start cause-specific management.
  • Alert ICU early.

Summary

Shock is a life-threatening circulatory disorder that leads to tissue hypoxia and a disturbance in microcirculation. The numerous causes of shock are classified into hypovolemic shock (e.g., following massive blood/fluid loss), cardiogenic shock (e.g., as a result of acute heart failure), obstructive shock (e.g., due to cardiac tamponade), and distributive shock (due to redistribution of body fluids), which is further classified into septic, anaphylactic, and neurogenic shock. Common clinical findings are hypotension and abnormal heart rate (most commonly tachycardia; bradycardia in neurogenic shock) accompanied by specific symptoms related to the cause of shock. Diagnosis is mostly clinical but measurement of functional parameters (e.g., PCWP, cardiac output, SVR) can help distinguish between the different types of shock. Management of shock involves circulatory support and treatment of the underlying cause. Shock is associated with a very high mortality rate.

Overview

Definitions

  • Shock (circulatory shock): a life-threatening disorder of the circulatory system that results in inadequate organ perfusion and tissue hypoxia, leading to metabolic disturbances and, ultimately, irreversible organ damage [1][2]
  • Shock index = pulse rate/systolic blood pressure
    • Normal range: 0.4–0.7
    • > 1 (positive shock index): consistent with circulatory shock

Types of shock

Overview of the types of shock [3][4][5]
Type Etiology of shock Typical hemodynamic parameters [6] Distinguishing clinical features Treatment options
Hypovolemic shock (includes hemorrhagic shock)
  • Fluid loss (from GI tract, skin, kidneys, or third spacing)
  • Hemorrhage
  • CVP
  • ↓↓ PCWP
  • ↓ CO
  • SVR
  • ↑ HR
  • ↓ SVO2
  • Cold, clammy extremities, slow capillary refill
  • Nondistended jugular veins (sometimes referred to as “empty heart”)
  • Decreased skin turgor, dry mucous membranes
  • Features of underlying etiology: e.g., signs of GI bleeding, diarrhea
  • Fluid resuscitation
  • Blood transfusion
  • Hemostatic control
Cardiogenic shock
  • Cardiac ischemia
  • Arrhythmias
  • Valvulopathy
  • Cardiotoxic substance exposure
  • CVP
  • PCWP
  • ↓↓ CO
  • SVR
  • Variable HR
  • ↓ SVO2
  • Cold, clammy extremities, poor capillary refill
  • Elevated JVP and distended neck veins (sometimes referred to as “full heart”)
  • Clinical features of heart failure
  • Features of underlying etiology: e.g., chest pain, palpitations, syncope, new/worsening murmur
  • Administration of IV fluids according to fluid responsiveness (see also “Fluid challenge”)
  • Inotropic support
  • Vasopressors
  • Diuretics
  • Treatment of refractory acute heart failure
Obstructive shock
  • Impairment of diastolic filling of the right ventricle (e.g., cardiac tamponade)
  • Obstruction of venous return (e.g., tension pneumothorax)
  • ↑ Ventricular afterload (e.g., massive pulmonary embolism)
  • CVP
  • ↑ or ↓ PCWP
  • ↓↓ CO
  • SVR
  • ↑ HR
  • ↓ SVO2
  • Cold, clammy extremities, poor capillary refill
  • Elevated JVP and distended neck veins
  • Features of underlying etiology: e.g., chest pain, diminished breath sounds, tracheal deviation, muffled heart tones, clinical features of DVT
  • Fluid resuscitation
  • Interventions to relieve obstruction, e.g.:
    • Pericardiocentesis
    • Needle thoracostomy followed by tube thoracostomy
    • Thrombolysis
Distributive shock Septic shock (most common)
  • Infection
  • Bacteremia
  • See “Etiology” in “Sepsis” for details.
  • CVP
  • Normal or PCWP
  • ↑ or ↓ CO
  • ↓↓ SVR
  • ↑ HR
  • ↑ SVO2
  • Early: flushed, warm skin, normal capillary refill
  • Late: cold, pale skin with delayed capillary refill
  • Features of sepsis: e.g., fever, SIRS criteria
  • Features of underlying infection: e.g., signs of typical pneumonia, meningismus
  • Fluid resuscitation
  • Vasopressors
  • Antibiotics
  • Infectious source control (e.g., abscess drainage, surgery)
Anaphylactic shock
  • Exposure to allergens (e.g., food, bee stings, drug reactions)
  • See “Etiology” in “Anaphylaxis” for details.
  • CVP
  • ↓↓ PCWP
  • ↑ or ↓ CO
  • ↓↓ SVR
  • ↑ HR
  • ↑ SVO2
  • Suspected or confirmed allergen exposure
  • Rapid onset (minutes to hours)
  • Clinical features of anaphylaxis
  • Epinephrine
  • Fluid resuscitation
Neurogenic shock
  • CNS injury (e.g., spinal cord injury ICH, TBI)
  • CVP
  • ↓↓ PCWP
  • ↓ CO
  • ↓↓ SVR
  • ↓ HR
  • Normal or ↑ SVO2
  • Flushed, warm skin
  • Bradycardia
  • Features of underlying etiology: neurological deficits (e.g., flaccid paralysis in spinal trauma)
  • Fluid resuscitation
  • Vasopressors
  • Atropine for bradycardia
Key CVP: right heart preload PCWP: pulmonary capillary wedge pressure (a surrogate marker for preload) CO: cardiac output (CO = HR × stroke volume) SVR: systemic vascular resistance (a surrogate marker for afterload) HR: heart rate SVO2: mixed venous content

Hemodynamic parameters in shock

Typical hemodynamic parameters of types of shock [3][4][5][6]
Type Estimated cardiac output (CO) Estimated preload (e.g., PCWP) Estimated afterload (e.g., SVR) Likelihood of fluid responsiveness
Hypovolemic
Cardiogenic
  • ↓↓
Obstructive
  • ↓↓
  • ↓ Or ↑
Distributive
  • Neurogenic: ↓
  • Septic and anaphylactic
    • Early: ↑
    • Late: ↓
  • Usually ↓
  • ↓↓

Stages of shock

The following stages may not occur in cases of sudden severe cardiovascular collapse , and the progression between stages in septic shock can be indistinct.

Stages of shock
Stage Characteristics
1. Preshock
  • Peripheral vasoconstriction
    • Manifests with cold, clammy extremities and increased capillary refill time
    • Decreased capillary hydrostatic pressure → increased absorption of interstitial fluids into intravascular space to help maintain blood pressure
    • Peripheral vasoconstriction may be absent in distributive shock.
  • Tachycardia (Patients with neurogenic shock may present with bradycardia.)
  • Oliguria
2. Shock (progressive phase)
  • Worsening hypotension
  • Hypoperfusion of peripheral tissues → generalized tissue hypoxia → anaerobic metabolism in the underperfused organs → lactic acidosis , which in turn causes:
    • Worsening tachypnea
    • Precapillary dilation and postcapillary constriction of the blood vessels → pooling and stasis of blood in the capillary bed → decreased cardiac output and formation of microthrombi in the capillaries → DIC and further hypoxic injury to tissues
  • Acidosis, cerebral hypoperfusion altered mental status
3. End-organ dysfunction (stage of decompensation)
  • Cerebral hypoxiaautonomic dysfunction
  • Myocardial ischemia → decreased cardiac output
  • Widespread cell necrosis causes:
    • Release of lysosomal enzymes → further tissue injury → worsening of shock
    • Activation of the immune system → release of cytokines → DIC, further tissue damage
  • Bowel ischemia → bacteremic sepsis
  • Can create a vicious cycle, leading to irreversible multiple organ failure

Clinical features

  • Patients may present at the emergency department with shock or develop shock at any time during hospitalization.
  • Screening for clinical features of shock in patients at risk can allow for early identification and treatment.
  • The clinical picture may vary depending on the stage of shock.
Clinical features of shock [7][8][9]
Feature Classic findings Atypical findings
Vital signs Heart rate
  • Normal or ↓
Blood pressure
  • Normal [7]
Respiratory rate
SpO2
  • Normal
Pulse pressure
  • ↑ In distributive shock
Clinical signs of end-organ hypoperfusion [8] Brain
  • Altered consciousness: variable
    • Agitation, confusion, disorientation
    • Lethargy, stupor, coma (e.g., low GCS score)
Kidney
  • Oliguria: urine output < 0.5 mL/kg/hour
  • Polyuria [10]
Skin
  • Slow capillary refill time
  • Cold
  • Mottled
  • Clammy/diaphoretic
  • Clinical signs of hypovolemia or volume depletion
  • Seen in certain types of distributive shock (e.g., early septic shock, neurogenic shock)
    • Normal capillary refill time
    • Warm
    • Flushed

Hypotension may be absent in some patients with shock. [7]

Signs of congestive heart failure alongside shock (e.g., JVP, crackles on lung auscultation) are suggestive of cardiogenic shock.

Initial management

Approach [4][7][8]

The following should be performed simultaneously:

  • Perform ABCDE survey: Identify the need for immediate airway or breathing intervention (e.g., basic airway maneuvers, supplemental O2).
  • Establish vascular access immediately: Simultaneously obtain blood samples for testing.
    • Preferred: ≥ 2 large-bore proximal peripheral IVs
    • Alternatives
      • IO access
      • Central venous line (CVL)
  • Begin immediate hemodynamic monitoring.
    • Continuous cardiac monitoring and pulse oximetry
    • Consider invasive monitoring for severe shock (e.g., central venous pressure, arterial line).
  • Classify the type of shock (see “Overview of types of shock”).
    • Check vital signs, signs of end-organ hypoperfusion, and other distinguishing clinical features.
    • Identify likely etiology of shock.
    • Perform rapid diagnostic studies, e.g., POCUS, portable CXR, ECG, serum lactate, ABG/VBG.
  • Provide immediate hemodynamic support: can be started for undifferentiated shock
    • Begin fluid resuscitation immediately if there are no clinical signs of fluid overload or diagnostic evidence of cardiogenic shock.
    • Consider a fluid challenge or passive leg raise test if fluid responsiveness is in doubt.
    • Determine the need for vasopressors, inotropes, or blood transfusions.
    • Determine the need for other critical therapy (e.g., corticosteroids for adrenal crisis, epinephrine for anaphylaxis, needle thoracostomy for tension pneumothorax).
  • Call for help early: critical care consult or rapid-response team
  • Frequently reassess the patient (e.g., for signs of deterioration or response to therapy): Consider advanced hemodynamic monitoring parameters.
  • Start specific management: according to the identified mechanism and its cause
    • Hypovolemic shock
    • Cardiogenic shock
    • Obstructive shock
    • Distributive shock

Act quickly: Provide immediate hemodynamic support and simultaneously try to identify the type of shock and the underlying cause in order to provide appropriate treatment.

Patients in shock are at risk of cardiopulmonary arrest; if the pulse is lost, start CPR!

Management of patients with severe shock can be recalled with the VIP rule: Ventilation as needed, Infuse IV fluids, and Pump vasopressors as needed. [4]

Respiratory support for patients with severe shock [4]

  • All patients
    • Provide supplementary O2 to avoid complications of hypoxemia.
    • Perform basic airway maneuvers as needed.
  • Indications for advanced airway maneuvers (e.g., endotracheal intubation
    • Airway protection: prevention of aspiration or obstruction due to, e.g., massive hematemesis, smoke inhalation injury, angioedema
    • Need for mechanical ventilation
  • Mechanical ventilation
    • Indications
      • Severe hemodynamic compromise: mechanical ventilation → ↓ MVO2 → improved heart function and perfusion
      • Hypercapnic respiratory failure and/or hypoxemic respiratory failure
    • Risks
      • Worsening hemodynamic compromise and periintubation cardiac arrest
      • See “High-risk indications for mechanical ventilation” for risk-reduction strategies.

Pulse oximetry measurements are unreliable in patients with shock due to peripheral hypoperfusion and/or vasoconstriction. Consider initial supplementary O2 for potential hypoxemia in all patients, regardless of pulse oximetry results. [4]

Diagnostics

Routine investigations can help identify the shock subtype but are not required for diagnosis. Consider further investigations if the subtype remains uncertain.

Shock is a clinical diagnosis.

Routine investigations

Findings allow for evaluation of the following:

  • Global hypoperfusion
    • Lactate (> 2 mmol/L) suggests tissue hypoperfusion and is associated with poorer outcomes [11][12]
    • ABG
      • Metabolic acidosis: base excess, HCO3-
      • Contraction alkalosis: HCO3-
  • Underlying etiology
    • CBC
      • Hb, Hct: suggests hemorrhage
      • Leukopenia or leukocytosis: suggests sepsis
    • BMP: BUN/Cr ratio, hyponatremia, and other laboratory findings of hypovolemia
    • Septic workup: e.g., urinalysis, blood cultures
    • ECG: Findings can show evidence of cardiogenic etiology, e.g., arrhythmias , acute coronary syndrome , signs of cardiomyopathy.
    • CXR
      • Pneumonia : suggests sepsis
      • Pulmonary edema , cardiac enlargement, or pleural effusions : suggests cardiogenic etiology
      • Pneumothorax : suggests obstructive etiology
  • Complications or end-organ dysfunction
    • Hypoglycemia or hyperglycemia
    • Electrolyte abnormalities
    • Renal function tests: BUN, creatinine, other signs of AKI or ATN (e.g., on urinalysis)
    • Liver chemistries: elevated in shock liver
    • Coagulation panel: suggestive of DIC, acute traumatic coagulopathy, or acute liver failure

In all patients with shock, immediately measure ABGs, lactate levels, capillary glucose, perform an ECG, and order a chest x-ray and general laboratory studies.

Compare any available previous studies to the patient's current test results. Previous studies can help determine if alterations to any laboratory or imaging studies are new and likely the cause of shock, or if they are caused by chronic conditions (e.g., CKD, chronic heart failure).

Further investigations

Further studies should be guided by clinical suspicion of the underlying cause.

Further diagnostic studies for patients in shock
Type of shock Studies to consider
Unclear after initial evaluation
  • Rapid assessment by cardiac echo [4][13]
Hypovolemic shock Hemorrhagic shock
  • Repeat CBC: Hb and Hct (can be normal initially)
  • Type and screen blood products.
  • To identify hemorrhage source
    • FAST scan: to identify intraabdominal hemorrhage
    • X-ray: to identify pelvic ring fractures, hemothorax
    • DRE: to identify active GI bleeding
Nonhemorrhagic shock
  • Insensible fluid losses: fever workup (see also “Diagnostics” in “Heatstroke”)
  • Third space fluid loss: CT abdomen to evaluate for pancreatitis or bowel obstruction
  • GI losses: See “Diagnostics” in “Nausea and vomiting” and “Diarrhea.”
  • Renal losses: urine electrolytes, urine creatinine
Cardiogenic shock
  • BNP and NT-proBNP compared to baseline
  • ECG: myocardial infarction, cardiac arrhythmias, signs of ventricular hypertrophy
  • Cardiac markers: troponin I and troponin T in acute coronary syndrome
  • Echocardiography: to identify valvular lesions, ventricular dysfunction, pericardial effusion
Obstructive shock
  • Echocardiography and POCUS: findings depend on the etiology
  • X-ray or CT chest: can identify pneumothorax
  • CT pulmonary angiography or V/Q scan: for suspected pulmonary embolism, aortic dissection
Distributive shock Septic shock
  • Cultures: e.g., blood and urine
  • Acute phase reactants: e.g., ESR, CRP, procalcitonin
  • See also “Septic workup.”
Anaphylactic shock
  • Diagnosis is mostly clinical.
  • Serum mast-cell tryptase if diagnosis is uncertain
  • See also “Diagnostic criteria for anaphylaxis.”
Neurogenic shock
  • Imaging studies can help identify the underlying injury (e.g., CT or MRI spine, CT or MRI brain).

If hemorrhagic shock is suspected, perform blood type and screen and crossmatch as soon as possible. Emergency issue blood products, e.g., Blood type O Rh-negative blood, can be given immediately; however, type-specific and crossmatched blood products are preferred as soon as they become available.

Ultrasound

Bedside evaluation of undifferentiated shock includes point-of-care ultrasound (POCUS) and echocardiographic techniques.

POCUS for undifferentiated shock [14][15][16]

Sequential POCUS examinations can help clinicians rapidly diagnose the subtype of shock and initiate the correct treatment. [17]

  • Focused cardiac ultrasound (FoCUS) is used to:
    • Rule out a large pericardial effusion [17]
    • Assess cardiac contractility
    • Evaluate for evidence of pulmonary embolism (e.g., RV dilation, D-sign) and/or tension pneumothorax
  • IVC ultrasound is used to: [18]
    • Estimate volume status
    • Predict fluid responsiveness, e.g., after a fluid challenge or passive leg raise test [19][20][21]
  • FAST and POCUS for suspected AAA are used to evaluate for intraperitoneal and/or intrathoracic bleeding. [17]
  • Lung POCUS can support a diagnosis of:
    • Hemorrhagic shock: signs of intrathoracic bleeding, e.g., hemothorax
    • Obstructive shock: signs of tension pneumothorax, e.g., absent lung sliding
    • Cardiogenic shock: signs of pulmonary fluid overload, e.g., bilateral diffuse B-lines
    • Septic shock: signs of consolidative pneumonia, e.g., Shred sign [16]

Bedside echocardiography

Simplified cardiac ultrasound can help identify pericardial effusion and indirect signs of right heart failure and cardiomyopathy. [22][23]

Rapid assessment by cardiac echo (RACE) [4][7]
Type of shock Possible findings
Hypovolemic shock
  • Small cardiac chambers
  • Contractility: high or preserved
Cardiogenic shock
  • Large cardiac chambers
  • Poor contractility
Obstructive shock
  • Cardiac tamponade
    • Small ventricles
    • Dilated inferior vena cava
    • Pericardial effusion
  • Pulmonary embolism or pneumothorax
    • Right ventricle: dilated
    • Left ventricle: small
Distributive shock
  • Normal cardiac chambers
  • Contractility is usually preserved.

Monitoring

Monitoring parameters can be used as treatment targets and should be tailored to the patient.

Monitoring parameters for patients with shock [7][24]
Variable Parameters
Clinical features in shock Vital signs
  • Heart rate: Aim for resolution of compensatory tachycardia and correction of arrhythmias.
  • Blood pressure: For most patients, target an MAP of ≥ 65 mm Hg.
Others
  • Volume status assessment
  • Resolution of signs of end-organ hypoperfusion, including:
    • Normal mental status
    • Normal capillary refill
    • Improvements in skin color and temperature
  • Urine output (for most patients): target > 0.5 mL/kg/hour
Laboratory Lactate
  • Aim for a lactate level ≤ 2 mEq/L.
  • Monitor for changes over time (i.e., lactate clearance). [25]
Base deficit (BD)
  • Measure of metabolic acidosis
  • Can aid the classification of hemorrhagic shock [26][27]
    • BD ≤ 2: frequently seen in patients with no shock
    • BD ≥10: frequently seen in patients with severe shock
SvO2 and ScvO2 [6][28][29]
  • Require access to central venous blood
  • Used as markers of oxygen delivery and consumption in the tissues [29]
  • Clinical applications
    • Estimating cardiac output in conjunction with other diagnostic tests
    • Used as a target in septic shock
  • Can be serially measured and interpreted along with other parameters of cardiopulmonary function [30]
    • SvO2 > 90%: marker of microcirculatory shunt ; confers a worse prognosis [6]
    • SvO2 < 65% (ScvO2 < 70%): possibly ↓ CO or anemia
    • SvO2 ≥ 65% (ScvO2 ≥ 70%) with:
      • Lactate ≤ 2 mEq/L: can be considered normal
      • Lactate > 2 mEq/L: possibly tissue hypoxia resulting from sepsis, or microcirculatory alterations
Device-based
Central venous pressure(CVP) [6][31]
  • Marker of right atrial pressure and, indirectly, venous return, ventricular preload, and volume status
  • Commonly used target for patients in shock: 8–12 mm Hg [6]
    • < 8 mm Hg: suggests hypovolemia
    • > 12 mm Hg: suggests volume overload
  • CVP is also affected by thoracic, pericardial, and abdominal pressures.
Cardiac function [6]
  • Normal cardiac output: 4–8 L/minute
  • Cardiac index: > 2.2 L/min/m2
Bedside echocardiography/POCUS
  • Rapid assessment by cardiac echo (RACE)
  • IVC diameter and IVC collapsibility

Signs of an inadequate response to fluid resuscitation include persistently heart rate, ↓ blood pressure, CVP, and ↓ urine output (< 0.5 mL/kg/hour).

Oxygen saturation from peripheral venous blood gases should not be misinterpreted as SvO2 or ScvO2.

  • Invasive hemodynamic monitoring: typically reserved for patients with severe shock
    • Most patients: urinary catheter to assess urine output
    • Patients requiring vasopressors [7]
      • Central venous line: can be used for CVP monitoring and ScVO2 sampling
      • Arterial line: can be used for invasive blood pressure monitoring and frequent ABG sampling
    • Select patients with refractory shock, RV dysfunction, or high risk of pulmonary edema with uncertain fluid status: pulmonary artery catheterization [7][32]
  • Protocolized resuscitation targets: e.g., consider lactate-guided fluid resuscitation strategy or early goal-directed therapy (EGDT) in sepsis.

Management

IV fluid resuscitation [7][13][33]

  • Clearly apparent hypovolemia: Aggressively replace volume deficit. [4]
    • IV fluid bolus over 10–30 minutes (using glucose-free isotonic crystalloids)
      • Adults: NS or lactated Ringer's 500–1000 mL IV bolus [33]
      • Children: NS or lactated Ringer's 10–20 mL/kg IV bolus [34][35]
      • Repeat as needed based on individual hemodynamic monitoring parameters. [36]
    • Hemorrhagic shock: Prioritize blood tranfusion as soon as it is available (replace blood losses with blood products).
  • Uncertain hypovolemia or high-risk patients: includes patients with risk factors for fluid overload or clinical signs of hypervolemia [37]
    • Assess fluid responsiveness, e.g., perform a fluid challenge or a passive leg raise . [24]
    • Fluid responsive: Repeat fluid challenge until there is no longer a response.
    • No response to IV fluids: Stop IV fluid boluses; start vasopressors or inotropes.
  • After stabilization
    • Continue with volume titration; further fluid challenges can be performed.
    • Proceed with other strategies for IV fluid therapy according to the patient's needs.

Patients with peripheral edema can still be fluid responsive if they have reduced effective arterial blood volume. [4]

Vasopressors [4]

  • Indications: treatment of various shock states in an effort to restore adequate arterial pressure and organ perfusion
    • Start immediately if hypotension is severe (simultaneously perform volume resuscitation).
    • Start in patients who are not fluid responsive following adequate IV fluid resuscitation.
  • Available agents
    • Choice is determined based on the underlying shock physiology, the desired pharmacological effects, and potential adverse effects.
    • First-line in undifferentiated shock: norepinephrine
  • Next steps
    • Adjust infusion according to hemodynamic monitoring parameters.
    • Titrate down as soon as possible until the patient is weaned.

Additional interventions

  • Corticosteroids (e.g., hydrocortisone ): not routinely recommended [38]
    • Start steroid stress dosing for patients with chronic corticosteroid use.
    • Give as treatment for an underlying disease: e.g., known or suspected adrenal crisis, early moderate ARDS or severe ARDS, adjunctive treatment for anaphylaxis.
  • If circulatory collapse is imminent, consider specialist consultation for mechanical circulatory support: e.g., ECMO, IABP, LVAD.
  • See also “Management of unstable tachycardia with a pulse” and “Unstable bradycardia.”

Patients with chronic corticosteroid use need steroid stress dosing to prevent adrenal crisis!

Vasopressors and inotropes

Vasopressors [3][39]

  • Most vasopressors have inotropic and vasoconstricting effects, i.e., they are inoconstrictor drugs.
  • Some are pure vasoconstrictor drugs.
  • All have varying degrees of dose-dependent chronotropic effects.
  • At higher dosages (e.g., norepinephrine > 0.5 mcg/kg/minute), all can cause harm.

Blood pressure does not always correlate with blood flow. Agents that increase blood pressure through vasoconstriction can impair tissue perfusion at high doses.

Although certain vasopressors, inotropes, and inodilators can be combined (e.g., to allow for individual agents to be used in moderate doses), this requires careful titration and specialist consultation.

Inoconstrictors

  • Mechanism of action
    • Vasoconstriction → SVR → ↑ BP
    • Inotropy → ↑ cardiac contractility → ↑ CO and ↑ MvO2
Inoconstrictor drugs [39][40][41][42]
Agent Continuous IV infusion dosages Pharmacology Clinical applications Adverse effects
Norepinephrine infusion (noradrenaline)
  • Initial dosage: 0.01–0.04 mcg/kg/minute
  • Titration increments: 0.02–0.04 mcg/kg/minute every 5–15 minutes
  • Usual dosage range: 0.01–0.4 mcg/kg/minute
  • Maximal dosage: 0.5–3.3 mcg/kg/minute [39]
  • α1 > β1
  • ↑↑ SVR , ↑↑ MAP
  • Unchanged/↑ CO, Unchanged/↓ HR
  • Half-life: ∼ 2 minutes
  • Heart rate is generally maintained because the β1-receptor-mediated increase in chronotropy is counterbalanced by reflex bradycardia resulting from the rise in mean arterial pressure.
  • Septic shock
  • Cardiogenic shock
  • Undifferentiated shock
  • Bradycardia
  • Tachyarrhythmia
  • Hypertension
  • Peripheral ischemia
Epinephrine infusion (adrenaline)
  • Initial dosage: 0.01–0.05 mcg/kg/minute
  • Titration increments: 0.02–0.05 mcg/kg/minute every 5–15 minutes
  • Usual dosage range: 0.01–0.3 mcg/kg/minute
  • Maximal dosage: 2 mcg/kg/minute
  • β12 > α1
  • ↑↑ CO, ↑↑ HR
  • SVR, ↑↑ MAP
  • Half-life: < 5 minutes
  • Cardiac arrest
  • Anaphylactic shock
  • Symptomatic bradycardia [43]
  • Septic shock
  • Hypertension
  • Cardiac ischemia
  • Ventricular arrhythmias
  • Sudden death
Dopamine infusion [41][42][44][45]
  • Initial dosage: 2–10 mcg/kg/minute
  • Titration increments: 2–5 mcg/kg/minute every 5–15 minutes
  • Usual dosage range: 2–20 mcg/kg/minute
  • Maximal dosage: 50 mcg/kg/minute [40][46]
  • β1 > α1
  • ↑↑ HR, ↑ CO
  • SVR, MAP
  • Half-life: 2 minutes
  • Septic shock [41]
  • Cardiogenic shock [47]
  • Symptomatic bradycardia [43]
  • Tachycardia
  • Ventricular arrhythmias
  • Hypertension
  • Peripheral ischemia
  • Cardiac ischemia
Key: α1 = α1-adrenergic receptor;β1 = β1-adrenergic receptor;β2 = β2-adrenergic receptor;AT1 = angiotensin II receptor type 1;SVR = systemic vascular resistance;MAP = mean arterial pressure;CO = cardiac output;HR = heart rate; BP = blood pressure

Pure vasoconstrictors

  • Mechanism of action: SVR without either significant ↑ cardiac contractility or ↑ HR
Pure vasoconstrictor drugs
Agent Continuous IV infusion dosages [40][41][42] Pharmacology [39][40][41][42] Clinical applications [40][41] Adverse effects #13620]
Phenylephrine infusion
  • Initial dosage: 0.1–0.3 mcg/kg/minute
  • Titration increments: 0.2–0.4 mcg/kg/minute every 5–15 minutes
  • Usual dosage range: 0.1–1.5 mcg/kg/minute
  • Maximal dosage: 6 mcg/kg/minute [47]
  • α1 only
  • ↑↑ SVR, ↑↑ MAP
  • Effective half-life: 5 minutes
  • Hypotension during anesthesia
  • Cardiogenic shock [47][48]
  • Refractory septic shock [49]
  • Shock with tachyarrhythmia [39]
  • Hypertension
  • Reflex bradycardia
  • Ischemia
Vasopressin infusion
  • Initial dosage: 0.01–0.03 units/minute
  • Titration increments: 0.005 units/minute every 5–15 minutes
  • Usual dosage range: 0.01–0.04 units/minute
  • Maximal dosage: 0.07 units/minute [41]
  • Fixed-dose infusion: 0.03–0.04 units/minute without titration (used as second-line in combination with another vasopressor, e.g., norepinephrine)
  • V1 (α1-like effect)
  • ↑↑ SVR, ↑↑ MAP
  • Effective half-life: ≤ 10 minutes
  • Refractory shock
  • Hypertension
  • Peripheral ischemia
  • Visceral ischemia
Key:α1 = α1-adrenergic receptor;V1 = vasopressin 1a receptor;SVR = systemic vascular resistance;MAP = mean arterial pressure;CO = cardiac output;HR = heart rate; BP = blood pressure

Inodilators

  • Mechanism of action
    • ↑ Cardiac contractility → ↑ CO
    • Peripheral vasodilation → SVR → afterload (combined with ↑ CO) → improved peripheral blood flow and tissue perfusion
Inodilator drugs
Agent Continuous IV infusion dosages [40][41][42] Pharmacology [39][40][41][42] Clinical applications [40][41] Adverse effects [40][50]
Dobutamine infusion
  • Initial dosage: 2.5–5 mcg/kg/minute
  • Titration increments: 2.5–5 mcg/kg/minute every 5–15 minutes
  • Usual dosage range: 2.5–20 mcg/kg/minute
  • Maximal dosage: 40 mcg/kg/minute [40][41][46]
  • β1 > β2 >> α1
  • ↑↑ CO, ↑ HR
  • Unchanged/↓ SVR, ↑/↓/unchanged MAP, ↓/unchanged PVR
  • Half-life: 2 minutes
  • Cardiogenic shock [39][47]
  • Septic shock [39]
  • Tachycardia
  • Ventricular arrhythmias
  • Hypertension
  • Cardiac ischemia
  • Hypotension
  • Eosinophilic myocarditis
Milrinone infusion
  • Initial dosage: 0.1–0.25 mcg/kg/minute
  • Usual dosage range: 0.25–0.75 mcg/kg/minute
  • Maximal dosage: 0.75 mcg/kg/minute
  • PDE-3 inhibitor (β12-like effect)
  • ↑↑ CO, ↑ HR
  • ↓↓ SVR, ↓/unchanged MAP, PVR
  • Half-life: 2–3 hours
  • Cardiogenic shock [41]
  • Hypotension
  • Ventricular arrhythmias
Key:α1 = α1-adrenergic receptor;β1 = β1-adrenergic receptor;β2 = β2-adrenergic receptor;PDE-3 = phosphodiesterase 3;SVR = systemic vascular resistance;PVR = pulmonary vascular resistance;MAP = mean arterial pressure;CO = cardiac output;HR = heart rate;BP = blood pressure

Hypovolemic shock

Etiology

  • Hemorrhage
    • Postpartum hemorrhage
    • Upper GI bleeding (e.g., variceal bleeding, PUD)
    • Blunt/penetrating trauma
    • Ruptured aneurysm or hematoma
    • Arteriovenous fistula
  • Nonhemorrhagic fluid loss
    • GI loss (e.g., diarrhea, vomiting)
    • Increased insensible fluid loss (e.g., burns)
    • Third space fluid loss (e.g., bowel obstruction, pancreatitis)
    • Renal fluid loss (e.g., adrenal insufficiency, drug-induced diuresis)

Pathophysiology

Loss of intravascular fluid volume → preload and SV ↓ CO → compensatory SVR and HR

Management [4][7][8]

The priority of immediate hemodynamic support is aggressive fluid resuscitation to achieve euvolemia. Further treatment depends on the etiologic category of hypovolemia (hemorrhagic vs. nonhemorrhagic).

Hemorrhagic shock

  • Blood products: Transfuse as soon as possible.
    • Ensure adequate vascular access and equipment (e.g., tubing) for blood products.
    • Consider emergency transfusion of uncrossmatched blood type O rhesus negative units.
    • Switch to crossmatched blood transfusions as soon as available.
    • If massive transfusion is expected : Consider transfusing packed RBC, FFP, and platelet concentrate in a 1:1:1 ratio. [51]
    • Consider the use of specialized infusers that allow for rapid administration of warmed blood.
  • Hemostatic control: should be prioritized
    • Begin immediate bedside measures: e.g., applying pressure, suturing, or stapling open wounds.
    • Consult specialist based on underlying etiology and risk stratification: e.g., surgery, gastroenterology, OB-GYN, interventional radiology.
    • Ensure definitive care: See Management of trauma patients,” ”Treatment of GI bleeding,” “Abnormal uterine bleeding,” “Antepartum hemorrhage,” and “Postpartum hemorrhage.”
  • Additional steps to consider [52][53][54]
    • Tranexamic acid for severe traumatic injury within 3 hours of injury [55][56]
    • Classification of hemorrhagic shock to help prioritize definitive care and monitor response to treatment
Classification of hemorrhagic shock
Class I II III IV
Blood loss (% of total blood volume) < 15% 15–30% 30–40% > 40%
Volume loss (in an average adult) ∼ 750 mL ∼ 750–1500 mL ∼ 1500–2000 mL > 2000 mL
Heart rate (bpm) 70–99 100–120 120–140 > 140
Systolic blood pressure Normal Normal
Pulse pressure Normal or ↑
Respiratory rate (rpm) Normal 20–30 30–40 > 35
Urine output > 30 mL/hour 20–30 mL/hour 5–15 mL/hour Absent
Mental status Normal Mildly anxious Anxious, confused Confused, lethargic

Upon suspecting hemorrhagic shock, perform blood grouping and cross-matching and have packed RBCs at hand for transfusion.

Uncrossmatched RBC type O negative units can be transfused if the hemorrhage is severe.

Nonhemorrhagic hypovolemic shock

  • Treatment of the underlying etiology to stop fluid losses, including:
    • GI losses: e.g., antiemetics for nausea and vomiting, antidiarrheal drugs
    • Third space fluid loss: e.g., treatment for pancreatitis or bowel obstruction
    • Increased insensible fluid losses: e.g., treatment for burns, antipyretic therapy for fever
    • Renal losses: e.g., cessation of diuretics, treatment for diabetes insipidus
  • Supportive care: e.g., treating any concomitant electrolyte abnormalities (e.g., hyponatremia, hypokalemia)
  • Next steps (once hemodynamically stable)
    • Continue with replacement of ongoing fluid loss as needed.
    • Attempt oral rehydration therapy.

Cardiogenic shock

Etiology

  • Myocardial infarction (MI): most common cause
  • Arrhythmias
  • Heart failure
  • Cardiomyopathy
  • Myocarditis
  • Ventricular septal defect, ventricular rupture
  • Valve defects: severe aortic or mitral regurgitation
  • Blunt cardiac trauma
  • Certain drugs (e.g., beta blockers, calcium channel blockers)

Pathophysiology

  • Underlying event causes dysfunction of the heart ↓ cardiac contractility and/or SV ↓ CO
  • Systemic circulation: ↓ CO and ↓ BP → catecholamines vasoconstriction and myocardial oxygen demand → ↑ renin-angiotensin-aldosterone system → further vasoconstriction and retention of sodium and water → shunting of blood to the brain and vital organs → insufficient perfusion of peripheral organs
  • Pulmonary circulation: ↓ cardiac contractility and/or SV → ↑ pulmonary hydrostatic pressure pulmonary edema

Management approach [57]

  • Determine the type of cardiogenic shock according to the classification of acute heart failure.
    • No evidence of congestion (“dry and cold”)
    • Evidence of congestion (“wet and cold”)
  • Tailor initial treatment according to type.
  • Provide supportive care.
    • Elevate the patient's head.
    • Provide respiratory support for AHF if there are signs of fluid overload.
    • Stop or modify medication that can worsen the symptoms (e.g., antihypertensives).
  • Treat the underlying cause (e.g., revascularization in MI).
  • See also “Management of acute heart failure.”
Management of cardiogenic shock [47][57][58]
Classification Treatment (see “Vasopressors and inotropes” for dosages)
Dry and cold
  • Fluid bolus only in cases of hypotension and/or PCWP < 15 mm Hg
  • Consider a fluid challenge (250–500 mL). [47][59]
    • Assess fluid responsiveness; consider additional bolus if the patient is responsive to fluid. [60]
    • Reassess for clinical signs of volume overload.
  • If shock persists, start a vasopressor, ideally, norepinephrine.
  • Administer inotropic support if hypoperfusion persists despite fluids and vasopressors. [46]
    • Dobutamine [39][47]
    • Milrinone [41]
    • Dopamine
Wet and cold
  • Administer inotropic therapy to maintain perfusion.
  • If shock persists, start a vasopressor (ideally, norepinephrine).
  • Once systolic BP is > 90 mm Hg, start diuretic therapy for AHF.
  • If symptoms persist, start treatment for refractory AHF.

IV fluids can worsen cardiogenic pulmonary edema in most cases of cardiogenic shock. Check fluid responsiveness prior to administration of fluid therapy.

Avoid inotropes in patients with left ventricular outflow tract obstruction (e.g., hypertrophic cardiomyopathy, aortic stenosis). [61]

Obstructive shock

Etiology

  • Diastolic filling
    • Cardiac tamponade
    • Constrictive pericarditis
    • Restrictive cardiomyopathy
  • Venous return
    • Tension pneumothorax
    • Intrathoracic tumor
    • Abdominal compartment syndrome
  • ↑ Ventricular afterload
    • Massive pulmonary embolism (PE)
    • Aortic dissection
    • Aortic stenosis
    • Large systemic emboli
    • Severe pulmonary hypertension

Pathophysiology [6]

  • Common mechanism: obstruction of the heart or its great vessels → inability of the heart to circulate blood → ↓ CO → compensatory SVR
  • Pulmonary embolism or severe PAH
    • Obstructions of the pulmonary vasculature → PCWP ↑ RV pressure → right heart failure
    • ↑ RV pressure → ↑ pressure on LV by the RV → ↓ LV diastolic filling → ↓ CO
    • Right heart failure → ↓ LV preload → ↓ CO
  • Tension pneumothorax
    • ↑ Intrathoracic pressure → venous return → preload → PCWP
    • ↑ Intrathoracic pressure → ↓ LV diastolic filling → ↓ CO
  • Cardiac tamponade
    • Pericardial pressure → ↑ RV pressure → ↓ RV diastolic filling → right heart failure
    • Pericardial pressure → ↑ LV pressure → ↓ LV diastolic filling → ↓ CO
    • ↑ LV pressure → PCWP → ↑ RV pressure
    • Right heart failure → ↓ LV preload → ↓ CO

Despite manifesting with high PCWP, many causes of obstructive shock (e.g., severe pulmonary hypertension, cardiac tamponade) are considered preload-dependent states. [6]

Elevation and equalization of pressures in all the cardiac chambers differentiate cardiac tamponade from other causes of obstructive shock.

Treatment

  • Provide immediate hemodynamic support.
    • Fluid resuscitation for patients who are preload-dependent and/or fluid responsive
    • Consider vasopressors or inotropic support.
  • Treatment based on the underlying cause, including:
    • Pericardiocentesis for cardiac tamponade
    • Thrombolytic therapy in PE or embolectomy in PE
    • Needle thoracostomy followed by chest tube placement or surgery for tension pneumothorax

Distributive shock

Etiology

  • Septic shock
    • Infection (especially gram-negative bacteria) and bacteremia
    • See “Etiology” in “Sepsis.”
  • Anaphylactic shock
    • Drug reactions; (e.g., sulfa drugs, contrast medium allergy)
    • Insect stings or bites (e.g., bee stings)
    • Food allergies (e.g., peanuts)
  • Neurogenic shock
    • Spinal cord injury (SCI)
    • Traumatic brain injury
    • Cerebral hemorrhage
    • Neuraxial anesthesia
  • Acute adrenal insufficiency
    • Stress in patients with underlying adrenal insufficiency
    • Sudden discontinuation of glucocorticoids after prolonged glucocorticoid therapy
    • See “Adrenal crisis” for details.

Pathophysiology

  • Common mechanism: vasodilation with or without capillary leakage → redistribution of fluid from the intravascular to the extravascular compartment
  • Septic shock
    • Specific mechanisms
      • Dysregulated host response to infection → capillary leakage and systemic vasodilation acute organ dysfunction
      • Circulating inflammatory cytokines → myocardial depression
    • Effect on cardiac output
      • Early: compensatory ↑ HR and contractility → ↑ CO (hyperdynamic state or “warm shock”)
      • Late: preload and direct myocardial depression by cytokines → ↓ CO (hypodynamic state or “cold shock”) [62]
  • Neurogenic shock
    • Specific mechanism: damage of autonomic pathways → loss of sympathetic vascular tone → unopposed vagal tone → peripheral vasodilation pooling of peripheral blood
    • Effect on cardiac output: can last days to weeks after spinal cord injury [63][64]
      • Unopposed vagal effect → ↓ HR
      • Catecholamines released from the sympathetic outflow → absent compensatory increases in HR and cardiac contractility
  • Anaphylactic shock
    • Specific mechanism: immunologic anaphylaxis (type I hypersensitivity reaction; IgE-mediated) or nonimmunologic anaphylaxis (not IgE-mediated) → degranulation of mast cells → massive histamine release → systemic vasodilation and increased capillary leakage
    • Effect on cardiac output
      • Early: compensatory ↑ HR and SV → ↑ CO
      • Late: ↓ vascular tone and capillary permeability → venous return → ↓ CO → ↓ coronary perfusion → ↓ contractility → ↓↓ CO [65]

Key treatment components

  • Volume expansion with fluid resuscitation
  • Reversal of vasodilation with vasopressors
  • Treatment of the underlying condition (e.g., antibiotics, removal of inciting allergens, spinal decompression surgery, glucocorticoid replacement)

Septic shock

Definition

  • Sepsis and both of the following, despite adequate fluid therapy (i.e., normovolemic patients):
    • Vasopressors required to maintain an MAP ≥ 65 mm Hg
    • Serum lactate > 18 mg/dL
  • See also “Sepsis definitions.”

Management of septic shock

See “Management of sepsis” for details on evaluation and definitive treatment of sepsis. The following recommendations relate to septic shock and are consistent with the 2016 and 2018 Surviving Sepsis Campaign guidelines: [12][36]

  • Begin interventions of the hour-1 bundle for sepsis, including:
    • Fluid resuscitation: rapid crystalloid infusion of 30 mL/kg [12][36]
    • Antibiotic therapy for sepsis
  • Consider protocolized resuscitation target strategies in addition to standard hemodynamic monitoring parameters.
  • The threshold for beginning vasopressors for septic shock should be low.
  • Consider corticosteroids (e.g., hydrocortisone ) for shock refractory to the first vasopressor.

6–10 L of IV fluids may be necessary during the first 24 hours. [66]

Protocolized resuscitation target strategies [12][36][67]

There is insufficient evidence to support the use of one target over the others in order to inform decisions about escalating hemodynamic support. [12]

  • Lactate-guided fluid resuscitation strategy [36][67]
    • If the initial lactate level is elevated (> 2 mmol/L), remeasure every 2–4 hours until normalized.
    • Treatment target: 20% decrease in serum lactate every 2–4 hours until normal
      • Down-trending lactate: Continue fluid resuscitation until normalized.
      • Persistent hypotension and/or lactate does not decrease as expected: aggressive fluid resuscitation and consider adding vasopressors.
    • Disadvantages [67][68]
      • Elevated lactate is not specific to sepsis.
      • This strategy may lead to fluid overload.
  • Early goal-directed therapy (EGDT) [12]
    • Treatment targets
      • CVP ≥ 8 cm H2O [12]
      • Central venous O2 saturation ≥ 70%
  • MAP treatment target: ≥ 65 mm Hg

Vasopressors for septic shock [12][36][67][68][69]

  • Indications: persistent hypotension during or after fluid resuscitation
  • Goal: maintain MAP ≥ 65 mm Hg [12]
  • Stepwise escalation (see “Vasopressors and inotropes” for dosages)
    • First-line: norepinephrine
    • If MAP is still low after norepinephrine:
      • Add vasopressin
      • OR add continuous IV epinephrine infusion (off-label)
    • To decrease norepinephrine dosage: Add vasopressin.
  • Additional options
    • Dopamine
      • Indicated as an alternative vasopressor in select cases (e.g., low risk of tachyarrhythmia, bradycardia) [12]
      • Should not be used for renal protection [12]
    • Dobutamine: Consider for hypoperfusion that persists despite fluids and initial vasopressors. [12]

Anaphylactic shock

Initial management [66][70][71]

  • Assess and secure the airway as needed (see “Airway management and ventilation in anaphylaxis”).
  • Remove allergen when possible (e.g., stop medication or IV contrast).
  • Administer epinephrine IM 1:1,000 as soon as possible and repeat as needed.
  • Provide immediate hemodynamic support with fluid resuscitation.
  • See also “Management of anaphylaxis” for further details.

Adjunctive treatment (antihistamines and corticosteroids) should only be administered after the initial resuscitation measures (IM epinephrine, fluids and/or vasopressors) have been given.

Refractory anaphylactic shock [66][70][71]

  • Refractory to repeated IM epinephrine and fluids: Start continuous IV epinephrine infusion 1:1,000,000 (1 mcg/mL).
  • Refractory to IV epinephrine infusion
    • Administer IV glucagon , especially if the patient is on a beta blocker.
    • Consider combination with other vasopressors: e.g., vasopressin, norepinephrine, dopamine, and phenylephrine.
    • Ensure adequate fluid status.
    • Consider consulting ECMO team if all other measures fail.

Neurogenic shock

Diagnosis

Neurogenic shock is a clinical diagnosis.

  • Classic presentation: hypotension, bradycardia, vasodilation [5]
  • Exclude other reasons for shock (e.g., other injuries).
  • Other neurological deficits may be present.

In a patient who develops low blood pressure following high-energy trauma, neurogenic shock is a diagnosis of exclusion that is made after hypovolemic and obstructive shock have been ruled out.

Management [72][73][74][75]

The following reviews the management of neurogenic shock from spinal cord injury, for brain injury-associated shock, see “Blood pressure control in brain injury.”

  • Treatment
    • Fluid resuscitation
      • First-line therapy
      • Avoid aggressive fluid boluses in patients with poor fluid responsiveness, because of the risk of fluid overload.
    • Vasopressors: commonly required as shock is often refractory to fluids
      • Lesions above T6: Consider norepinephrine or dopamine. [75]
      • Lesions below T6: Consider phenylephrine. [75]
    • Consider atropine or cardiac pacing to treat bradycardia (see “Unstable bradycardia” for details). [76]
    • Consult a spine surgeon early to evaluate whether the patient is a candidate for urgent spinal decompression.
  • Monitoring
    • Insert a urinary catheter early. [77]
    • Hemodynamic targets should be individualized in consultation with a specialist.
      • Avoid hypotension (systolic BP < 90 mm Hg).
      • Consider maintaining a MAP of 75–90 mm Hg during the first 3–7 days after spinal cord injury. [72][73][74]
      • Laboratory perfusion parameters (e.g., lactate, base deficit) are typically more reliable markers of perfusion than MAP in patients with SCI.
    • Monitor for cardiovascular complications (e.g., ACS, stroke).
  • Supportive care [75]
    • Prevent hypothermia ; monitor temperature frequently and use warm IV fluids or warming devices as needed.
    • Patients may have allodynia; careful patient handling and pain management are required.
    • Vasovagal responses can be increased and can lead to refractory shock.
    • Autonomic dysreflexia and vascular dysfunction may be present and can complicate management and recovery. [76][78]

Patients with neurogenic shock can have increased vasovagal responses to common procedures (e.g., suctioning, endotracheal intubation), which can trigger rapid changes in heart rate and blood pressure and increase the risk for complications and refractory shock. [79]

Complications

  • General
    • Cardiovascular collapse
    • Acute renal failure (due to prolonged tissue hypoperfusion)
    • Delirium
  • Specific shock subtypes
    • Airway obstruction (anaphylactic shock)
    • Pulmonary edema (cardiogenic shock)
    • Disseminated intravascular coagulation (hemorrhagic shock and septic shock)
  • Iatrogenic
    • Nosocomial infections: e.g., CLABSI, VAP
    • Complications of mechanical ventilation
    • Complications of IV fluid therapy

We list the most important complications. The selection is not exhaustive.

Refractory shock

Rescue therapies for shock are for patients who remain in shock despite adequate treatment of the underlying cause. These treatments should be given in consultation with a specialist, and they include: [3]

  • Corticosteroids (e.g., hydrocortisone): for suspected critical illness-related corticosteroid insufficiency (CIRCI) [38][80]
    • Diagnosis of CIRCI is based on the presence of critical illness plus one of the following :
      • Increase in cortisol level of < 9 mcg/dL after an ACTH stimulation test
      • Random plasma cortisol < 10–15 mcg/dL [38][80]
      • Positive hemodynamic response (e.g., reduced need for vasopressors) to hydrocortisone 50–300 mg IV
    • See also “Adrenal crisis.”
  • Bicarbonate (e.g., 8.4% sodium bicarbonate ) [3]
    • For correction of severe metabolic acidosis (e.g., pH < 7.1)
    • Tailor treatment to the patient's bicarbonate deficit and monitor HCO3 levels and pH frequently (e.g., initially every 2 hours). [81]
  • Mechanical circulatory support
    • Consider ECMO for severe ARDS, refractory respiratory failure, or refractory heart failure.
    • Consider IABP and LVAD for refractory cardiogenic shock.

Related One-Minute Telegram

  • One-Minute Telegram 137-2025-3/3: It's ICU cuffing season with noninvasive blood pressure monitoring
  • One-Minute Telegram 136-2025-1/3: Capillary refill time gets personal in septic shock
  • One-Minute Telegram 85-2023-1/3: ECLS no panacea for ischemic cardiogenic shock
  • One-Minute Telegram 37-2021-2/3: Vasopressin plus methylprednisolone for cardiac arrest: Can a cocktail save lives?
  • One-Minute Telegram 8-2020-2/3: Should a cocktail of vitamin C, thiamine, and hydrocortisone be given to all patients with septic shock?

Interested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below.

External Resources

References

  1. Rhodes A, Evans LE, Alhazzani W, et al. "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016". Intensive Care Med. 43(3). :304-377. (2017)
  2. Levy MM, Evans LE, Rhodes A. "The Surviving Sepsis Campaign Bundle: 2018 update". Intensive Care Med. 44(6). :925-928. (2018)
  3. Walls R, Hockberger R, Gausche-Hill M. "Rosen's Emergency Medicine". Elsevier Health Sciences. (2018). ISBN: 9780323354790
  4. Hernández G, Ospina-Tascón GA, Damiani LP, et al. "Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock". JAMA. 321(7). :654. (2019)
  5. Rhee C, Chiotos K, Cosgrove SE, et al. "Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure". Clinical Infectious Diseases. (2020)
  6. Kalil AC, Gilbert DN, Winslow DL, Masur H, Klompas M. "Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines". Clinical Infectious Diseases. 66(10). :1631-1635. (2017)
  7. Summers RL, Baker SD, Sterling SA, Porter JM, Jones AE. "Characterization of the spectrum of hemodynamic profiles in trauma patients with acute neurogenic shock". J Crit Care. 28(4). :531.e1-531.e5. (2013)
  8. Kwon BK, Tetreault LA, Martin AR, et al. "A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on Hemodynamic Management". Global Spine J. 14(3_suppl). :187S-211S. (2024)
  9. "American College of Surgeons, American Congress of Rehabilitation Medicine, Best practices guidelines: Spine injury". https://www.facs.org/media/k45gikqv/spine_injury_guidelines.pdf. [2022-03-01]
  10. Walters BC, Hadley MN, Hurlbert RJ, et al. "Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries". Neurosurgery. 60(CN_suppl_1). :82-91. (2013)
  11. Consortium for Spinal Cord Medicine.. "Early acute management in adults with spinal cord injury: A clinical practice guideline for health-care professionals.". J Spinal Cord Med. 31(4). :403-79. (2008)
  12. Popa C, Popa F, Grigorean VT, et al. "Vascular dysfunctions following spinal cord injury.". J Med Life. 3(3). :275-85. (2010)
  13. Bonner S, Smith C. "Initial management of acute spinal cord injury". Continuing Education in Anaesthesia Critical Care & Pain. 13(6). :224-231. (2013)
  14. Eldahan KC, Rabchevsky AG. "Autonomic dysreflexia after spinal cord injury: Systemic pathophysiology and methods of management". Auton Neurosci. 209. :59-70. (2018)
  15. Hagen E, Rekand T, Grønning M, Færestrand S. "Kardiovaskulære følgetilstander etter ryggmargsskade". Tidsskr Nor Legeforen. 132(9). :1115-1120. (2012)
  16. Vincent J-L, De Backer D. "Circulatory Shock". N Engl J Med. 369(18). :1726-1734. (2013)
  17. Cecconi M, De Backer D, Antonelli M, et al. "Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine". Intensive Care Med. 40(12). :1795-1815. (2014)
  18. Vincent J-L, Ince C, Bakker J. "Clinical review: Circulatory shock - an update: a tribute to Professor Max Harry Weil". Critical Care. 16(6). (2012)
  19. Thomas D, Wee M, Clyburn P, et al. "Blood transfusion and the anaesthetist: management of massive haemorrhage". Anaesthesia. 65(11). :1153-1161. (2010)
  20. American College of Surgeons. "ATLS Advanced Trauma Life Support". American College of Surgeons. ISBN: 9781880696521
  21. Cannon J, Khan M, Raja A. "Damage control resuscitation in patients with severe traumatic hemorrhage". J Trauma Acute Care Surg. 82(3). :605-617. (2017)
  22. Lier H, Goossen K, Kugler C. "Inhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update". Eur J Trauma Emerg Surg. 51(1). (2025)
  23. CRASH-2 trial collaborators., Shakur H, Roberts I, et al. "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial". Lancet. 376(9734). :23-32. (2010)
  24. CRASH-2 collaborators., Roberts I, Shakur H, et al. "The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial". Lancet. 377(9771). :1096-101, 1101.e1-2. (2011)
  25. Ponikowski P, Voors AA, Anker SD, et al. "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure". Eur Heart J. 37(27). :2129-2200. (2016)
  26. Van Diepen S, Katz JN, Albert NM, et al. "Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association". Circulation. 136(16). (2017)
  27. Pollard S, Edwin SB, Alaniz C. "Vasopressor and Inotropic Management Of Patients With Septic Shock.". P T. 40(7). :438-50. (2015)
  28. Long B, Koyfman A, Gottlieb M. "Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature". J Emerg Med. 55(5). :635-646. (2018)
  29. Yealy DM, Callaway C. "Emergency Department Critical Care". Oxford University Press. (2013). ISBN: 9780199779123
  30. Yancy CW, Jessup M, Bozkurt B, et al. "2013 ACCF/AHA Guideline for the Management of Heart Failure". J Am Coll Cardiol. 62(16). :e147-e239. (2013)
  31. Hollenberg SM. "Vasoactive Drugs in Circulatory Shock". Am J Respir Crit Care Med. 183(7). :847-855. (2011)
  32. Jentzer JC, Coons JC, Link CB, Schmidhofer M. "Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit". J Cardiovasc Pharmacol Ther. 20(3). :249-260. (2014)
  33. Gersh BJ, Maron BJ, Bonow RO, et al. "2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy". Circulation. 124(24). (2011)
  34. Töpel I, Zorger N, Steinbauer M. "Inflammatory diseases of the aorta". Gefässchirurgie. 21(S2). :87-93. (2016)
  35. Ploumis A, Yadlapalli N, Fehlings MG, Kwon BK, Vaccaro AR. "A systematic review of the evidence supporting a role for vasopressor support in acute SCI". Spinal Cord. 48(5). :356-362. (2009)
  36. Ruiz IA, Squair JW, Phillips AA, et al. "Incidence and Natural Progression of Neurogenic Shock after Traumatic Spinal Cord Injury". J Neurotrauma. 35(3). :461-466. (2018)
  37. Kounis N, Soufras G, Hahalis G. "Anaphylactic shock: Kounis hypersensitivity-associated syndrome seems to be the primary cause". North American Journal of Medical Sciences. 5(11). :631. (2013)
  38. Campbell RL, Li JTC, Nicklas RA, Sadosty AT. "Emergency department diagnosis and treatment of anaphylaxis: a practice parameter". Ann Allergy Asthma Immunol. 113(6). :599-608. (2014)
  39. Lieberman P, Nicklas RA, Randolph C, et al. "Anaphylaxis—a practice parameter update 2015". Annals of Allergy, Asthma & Immunology. 115(5). :341-384. (2015)
  40. Simmons J, Ventetuolo CE. "Cardiopulmonary monitoring of shock". Curr Opin Crit Care. 23(3). :223-231. (2017)
  41. "Hemorrhagic Shock". http://www.cvphysiology.com/Blood%20Pressure/BP031. [2014-04-28]
  42. Drucker WR, Chadwick CD, Gann DS. "Transcapillary refill in hemorrhage and shock.". Arch Surg. 116(10). :1344-53. (1981)
  43. Jentzer JC, Vallabhajosyula S, Khanna AK, et al. "Management of Refractory Vasodilatory Shock". Chest. 154(2). :416-426. (2018)
  44. Overgaard CB, Dzavík V. "Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease.". Circulation. 118(10). :1047-56. (2008)
  45. Jentzer JC, Hollenberg SM. "Vasopressor and Inotrope Therapy in Cardiac Critical Care". J Intensive Care Med. :088506662091763. (2020)
  46. Link MS, Berkow LC, Kudenchuk PJ, et al. "Part 7: Adult Advanced Cardiovascular Life Support". Circulation. 132(18 suppl 2). :S444-S464. (2015)
  47. Gamper G, Havel C, Arrich J, et al. "Vasopressors for hypotensive shock". Cochrane Database of Systematic Reviews. (2016)
  48. Avni T, Lador A, Lev S, et al. "Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis". PLoS ONE. 10(8). :e0129305. (2015)
  49. Goertz AW, Lindner KH, Schültz W, et al. "Influence of Phenylephrine Bolus Administration on Left Ventricular Filling Dynamics in Patients with Coronary Artery Disease and Patients with Valvular Aortic Stenosis". Anesthesiology. 81(1). :49-58. (1994)
  50. Dellinger RP, Levy MM, Rhodes A, et al. "Surviving Sepsis Campaign". Crit Care Med. 41(2). :580-637. (2013)
  51. Bistola V, Arfaras-Melainis A, Polyzogopoulou E, et al. "Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice". Cardiac Failure Review. 5(3). :133-139. (2019)
  52. Russell FM, Ehrman RR, Cosby K, et al. "Diagnosing Acute Heart Failure in Patients With Undifferentiated Dyspnea: A Lung and Cardiac Ultrasound (LuCUS) Protocol". Acad Emerg Med. 22(2). :182-191. (2015)
  53. Martindale JL, Wakai A, Collins SP, et al. "Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis". Acad Emerg Med. 23(3). :223-242. (2016)
  54. Hendin A, Koenig S, Millington SJ. "Better With Ultrasound". Chest. 158(5). :2082-2089. (2020)
  55. Perera P, Mailhot T, Riley D, Mandavia D. "The RUSH Exam: Rapid Ultrasound in SHock in the Evaluation of the Critically lll". Emerg Med Clin North Am. 28(1). :29-56. (2010)
  56. Gaskamp M, Blubaugh M, McCarthy LH, Scheid DC. "Can Bedside Ultrasound Inferior Vena Cava Measurements Accurately Diagnose Congestive Heart Failure in the Emergency Department? A Clin-IQ.". J Patient Cent Res Rev. 3(4). :230-234. (2016)
  57. Long E, Oakley E, Duke T, Babl FE. "Does Respiratory Variation in Inferior Vena Cava Diameter Predict Fluid Responsiveness". Shock. 47(5). :550-559. (2017)
  58. Pourmand A, Pyle M, Yamane D, Sumon K, Frasure SE. "The utility of point-of-care ultrasound in the assessment of volume status in acute and critically ill patients.". World J Emerg Med. 10(4). :232-238. (2019)
  59. Corl KA, George NR, Romanoff J, et al. "Inferior vena cava collapsibility detects fluid responsiveness among spontaneously breathing critically-ill patients". J Crit Care. 41. :130-137. (2017)
  60. Russell FM, Rutz M, Pang PS. "Focused Ultrasound in the Emergency Department for Patients with Acute Heart Failure.". Card Fail Rev. 1(2). :83-86. (2015)
  61. Sorensen B, Hunskaar S. "Point-of-care ultrasound in primary care: a systematic review of generalist performed point-of-care ultrasound in unselected populations". Ultrasound J. 11(1). (2019)
  62. Malbrain MLNG, Langer T, Annane D, et al. "Intravenous fluid therapy in the perioperative and critical care setting: Executive summary of the International Fluid Academy (IFA)". Ann. Intensive Care. 10(1). (2020)
  63. Finfer S, Myburgh J, Bellomo R. "Intravenous fluid therapy in critically ill adults". Nat Rev Nephrol. 14(9). :541-557. (2018)
  64. Moritz ML, Ayus JC. "Maintenance Intravenous Fluids in Acutely Ill Patients". N Engl J Med. 373(14). :1350-1360. (2015)
  65. Gelbart B. "Fluid Bolus Therapy in Pediatric Sepsis: Current Knowledge and Future Direction". Front Pediatr. 6. (2018)
  66. Carsetti A, Cecconi M, Rhodes A. "Fluid bolus therapy: monitoring and predicting fluid responsiveness.". Curr Opin Crit Care. 21(5). :388-94. (2015)
  67. Marik PE, Weinmann M. "Optimizing fluid therapy in shock.". Curr Opin Crit Care. 25(3). :246-251. (2019)
  68. Annane D, Pastores SM, Rochwerg B, et al. "Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I)". Crit Care Med. 45(12). :2078-2088. (2017)
  69. Holmes CL, Walley KR. "The evaluation and management of shock". Clin Chest Med. 24(4). :775-789. (2003)
  70. Legrand M, Payen D. "Understanding urine output in critically ill patients". Annals of Intensive Care. 1(1). (2011)
  71. Gyawali B, Ramakrishna K, Dhamoon AS. "Sepsis: The evolution in definition, pathophysiology, and management". SAGE Open Medicine. 7. :205031211983504. (2019)
  72. Privette AR, Dicker RA. "Recognition of hypovolemic shock: using base deficit to think outside of the ATLS box". Critical Care. 17(2). :124. (2013)
  73. Mutschler M, Nienaber U, Brockamp T, et al. "Renaissance of base deficit for the initial assessment of trauma patients: a base deficit-based classification for hypovolemic shock developed on data from 16,305 patients derived from the TraumaRegister DGU®". Critical Care. 17(2). :R42. (2013)
  74. De Backer D. "Detailing the cardiovascular profile in shock patients". Critical Care. 21(S3). (2017)
  75. Walley KR. "Use of Central Venous Oxygen Saturation to Guide Therapy". Am J Respir Crit Care Med. 184(5). :514-520. (2011)
  76. "Saint Louis Encephalitis". https://web.archive.org/web/20220703185947/https://www.cdc.gov/sle/symptoms/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fsle%2Ftechnical%2Fsymptoms.html. [2018-12-04]
  77. De Backer D, Vincent JL. "Should we measure the central venous pressure to guide fluid management? Ten answers to 10 questions.". Crit Care. 22(1). :43. (2018)
  78. Hunt SA, Abraham WT, et al. "2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults". Circulation. 119(14). (2009)
  79. Lee SM, An WS. "New clinical criteria for septic shock: serum lactate level as new emerging vital sign". Journal of Thoracic Disease. 8(7). :1388-1390. (2016)
  80. Cooper MS, Stewart PM. "Corticosteroid Insufficiency in Acutely Ill Patients". N Engl J Med. 348(8). :727-734. (2003)
  81. Kurtz I. "Acid-Base Case Studies". Trafford Publishing. (2004). ISBN: 9781553956013